SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stressgen (VSE: SSB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andy Patton who wrote ()4/10/1997 11:26:00 AM
From: don jackson   of 236
 
StressGen was featured as the "Hot Stock" in yesterday's Financial
Post. It was a very positive article indicating that institutional
investors have been building their positions in the stock. The deal with Genzyme was discussed indicating that the type of deal arranged is not typical in Canada but common in the US. Apparently what StressGen signed over was partial ownership of a technology they licensed for a minimal amount of money last year. So they've made a
quick and leveraged return on that investment.

Their "burn rate" is sustainable for product R & D with 12 month targets to $8.00/share with longer-term returns showing greater promise given the technologies involved. Most of their technologies are not covered under joint ventures yet, so there is great potential for agreements with other companies.

Overall a very encouraging article.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News